Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service BPH procedures cases in Idaho: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 16 | 1,104 | 37% |
| 2020 | 15 | 1,050 | 40% |
| 2021 | 14 | 1,170 |
TURP, laser enucleation and vaporization, UroLift, Rezum. Professional codes (what the surgeon bills): CPT 52601, 52648, 52649, 52441, 52442, 53854, 55874.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 86% of the cases CMS names in Idaho; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 202 | 14,148−8%/yr | −8%/yr | 4.2 | 48% | 14,100 in 2030−0.1%/yr |
| Arizona | 79 | 6,117−8.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 20 | 895−1%/yr | −1%/yr | 4.41.2× | 21% | 1,470 in 2030+8.6%/yr |
| Hysterectomy, hysteroscopy & ablation |
BPH procedures in every state, and its device makers · Every procedure market in Idaho · Every state · Compare with California
| 2024 |
| 1,020 |
| 52% |
| 2025 est. | ≈ 930 | – |
| 2026 est. | ≈ 1,040 | – |
| 43% |
| 2022 | 13 | 1,002 | 47% |
| 2023 | 12 | 999 | 50% |
| 2024 | 17 | 1,020 | 52% |
| 2025 from claims | – | 929 853–983 | 54% |
| 2026 forecast | – | 1,043 917–1,203 | 49% |
| 2027 forecast | – | 1,075 919–1,281 | 49% |
| 2028 forecast | – | 1,108 925–1,357 | 49% |
| 2029 forecast | – | 1,142 933–1,433 | 49% |
| 2030 forecast | – | 1,178 944–1,509 | 48% |
In 2025, 1% inpatient hospital, 60% hospital outpatient, 36% surgery center, 3% office. The share outside the hospital has moved +17 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center | Office |
|---|---|---|---|---|
| 2026 · ~1,000 | ~13 | ~640 | ~380 | ~11 |
| 2027 · ~1,100 | ~13 | ~670 | ~390 | ~3 |
| 2028 · ~1,100 | ~14 | ~690 | ~410 | ~0 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: office about 0% (3% in 2025), hospital outpatient about 62% (60% in 2025).
| −8.2%/yr |
| 8.2 |
| 55% |
| 6,220 in 2030+0.3%/yr |
| Washington | 49 | 3,507−5.1%/yr | −5.1%/yr | 4.5 | 27% | 3,370 in 2030−0.6%/yr |
| Colorado | 49 | 2,851−4%/yr | −4%/yr | 5.8 | 43% | 2,530 in 2030−2%/yr |
| Oregon | 25 | 1,987−8.3%/yr | −8.3%/yr | 4.7 | 44% | 1,720 in 2030−2.4%/yr |
| Utah | 29 | 1,113−15%/yr | −15%/yr | 5.1 | 14% | 1,080 in 2030−0.5%/yr |
| Nevada | 22 | 901−13%/yr | −13%/yr | 3.1 | 60% | 1,050 in 2030+2.5%/yr |
| Montana | 12 | 679−16%/yr | −16%/yr | 3.6 | 7% | 580 in 2030−2.5%/yr |
| Alaska | 6 | 477+20%/yr | +20%/yr | 4.0 | 59% | 640 in 2030+5%/yr |
| New Mexico | 10 | 453−21%/yr | −21%/yr | 2.0 | 7% | 410 in 2030−1.6%/yr |
| Hawaii | 5 | 293−11%/yr | −11%/yr | 2.3 | 43% | 390 in 2030+5%/yr |
| Wyoming | 4 | 186−7.9%/yr | −7.9%/yr | 1.7 | 39% | 240 in 2030+4.1%/yr |
| 5 |
| 440+2.5%/yr |
| +2.5%/yr |
| 2.41.0× |
| 9% |
| 690 in 2030+7.8%/yr |
| Incontinence, prolapse & sacral neuromodulation | 4 | 408+1.3%/yr | +1.3%/yr | 2.01.1× | 11% | 900 in 2030+14%/yr |
| Prostatectomy & nephrectomy | 5 | 276+4.7%/yr | +4.7%/yr | 1.51.2× | 0% | 260 in 2030−1.1%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Teleflex leads with 34% of company spending on these surgeons in 2025, −11 pts on 2024.
In 2025, 6 companies reported engagement with Idaho’s surgeons worth $4,110 in consulting, speaking, meals and travel tied to these products, about $242 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.